1. Signaling Pathways
  2. Immunology/Inflammation
  3. CTLA-4

CTLA-4 

Cytotoxic T-lymphocyte-associated protein 4; CD152

细胞毒性 T 淋巴细胞相关蛋白 4 (CTLA-4),也称为 CD152,是一种属于 CD28 免疫球蛋白亚家族的抑制性受体。CTLA-4 主要由 T 细胞表达。CTLA-4 的配体 CD80 和 CD86 通常位于抗原呈递细胞表面,可以结合 CD28 或 CTLA-4。配体与 CTLA-4 的相互作用可抑制 T 细胞反应。由于其抑制作用,CTLA-4 是 T 细胞稳态和自我耐受的重要调节器。CTLA-4 发挥其抑制功能的机制可分为细胞内在机制(影响表达 CTLA-4 的 T 细胞)或细胞外在机制(影响次级细胞)。CTLA-4 被公认为关键的免疫检查点,并作为自身免疫和癌症领域的治疗靶点获得了显著的发展势头。

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also known as CD152, is an inhibitory receptor belonging to the CD28 immunoglobulin subfamily. CTLA-4 is expressed primarily by T cells. The ligands of CTLA-4, CD80 and CD86, are typically found on the surface of antigen-presenting cells and can either bind CD28 or CTLA-4. The interactions of the ligands with CTLA-4 serve to inhibit T cell responses. Because of its dampening effect, CTLA-4 is a crucial regulator of T-cell homeostasis and self-tolerance. The mechanisms by which CTLA-4 exerts its inhibitory function can be categorized as either cell-intrinsic (affects the CTLA-4 expressing T-cell) or cell-extrinsic (affects secondary cells). CTLA-4 is well recognized as a key immune checkpoint and has gained significant momentum as a therapeutic target in the field of autoimmunity and cancer.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P990080
    Sovipostobart Inhibitor
    Sovipostobart 是一种人源的免疫球蛋白 G1-kappa、抗 CTLA-4 单克隆抗体,具有可切割的前结构域。Sovipostobart 是一种免疫刺激剂和抗肿瘤药。
    Sovipostobart
  • HY-P99714
    Lorigerlimab

    洛瑞格利单抗

    Inhibitor
    Lorigerlimab (MGD019) 是一种双特异性 IgG4 双亲和力再靶向抗体 (DART)。Lorigerlimab 可以阻断 PD-1CTLA-4,并改善 T 细胞反应。Lorigerlimab 可用于转移性去势抵抗性前列腺癌 (mCRPC) 的研究
    Lorigerlimab
  • HY-P990739
    Evalstotug
    Evalstotug 是一种抗 CTLA4 的人源 IgG1 κ 单克隆抗体。Evalstotug 的同型对照产品:Human IgG1 kappa, Isotype Control (HY-P99001)。
    Evalstotug
目录号 产品名 / 同用名 种属 表达系统
目录号 产品名 / 同用名 应用 反应物种